Alnylam price target raised to $338 from $300 at Scotiabank
Scotiabank raised the firm’s price target on Alnylam (ALNY) to $338 from $300 and keeps an Outperform rating on the shares. The firm expects Amvuttra, the first transthyretin silencer to enter the ...
Devdiscourse13h
FDA Expands Alnylam Heart Drug Approval Amid Health Policy Shifts
The FDA's approval of Alnylam's heart disease drug expands treatment options in a market poised for growth. Meanwhile, the ...
Devdiscourse5h
Health Headlines: Measles Outbreak, Drug Approvals, and Global Health Challenges
Recent health updates include a rise in measles cases in Texas and New Mexico, expansion of Alnylam's heart disease drug ...
Stock market firms. S&P 500, Dow up for week. FedEx, Nike warn on outlooks
US stocks end up with S&P 500 and Dow gaining on the week. Focus returns to the economy and tariffs. FedEx and Nike fall ...